US Patent

US9943537 — Antitumor agent and antitumor effect enhancer

Method of Use · Assigned to Taiho Pharmaceutical Co Ltd · Expires 2034-09-05 · 8y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of treating cancer using a combination of a drug containing trifluridine and tipiracil hydrochloride and an anti-VEGF or anti-EGFR antibody.

USPTO Abstract

Provided is a novel method for treating a cancer using an FTD/TPI combination drug, which shows remarkably excellent antitumor effect and small adverse effects. An antitumor agent, in which a combination drug containing trifluridine and tipiracil hydrochloride at a molar ratio of 1:0.5 and an anti-VEGF antibody or anti-EGFR antibody are administered in combination.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3659`	—
`U-3659`	—

Patent Metadata

Patent number: US9943537
Jurisdiction: US
Classification: Method of Use
Expires: 2034-09-05
Drug substance claim: No
Drug product claim: No
Assignee: Taiho Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.